Borrelia garninii Antigen BA121GVS

$877.00

Summary

Virion/Serion Immunologics Antigen for research use (RUO)
Borrelia garninii Antigen, recombinant
Suitable for detection of IgA, IgG & IgM antibodies in ELISA
Lot specific concentration, specified in mg/mL
1 mg

SKU: BA121GVS Category: Infectious disease proteins Tags: antigen, Borrelia

Weight	1 lbs
Dimensions	9 × 5 × 2 in
target	Borrelia garninii
species reactivity	Borrelia garinii (lyme disease)
applications	ELISA
assay type	Indirect & quantitative
available size	1 mg

Borrelia garninii Antigen BA121GVS

kit
Research area Infectious Disease
Storage Store at -65°C or lower. Avoid repeated freeze-thaw cycles. Sonicate before use. 10 years from date of manufacture (under recommended storage conditions).
Form liquid
Associated products Borrelia garninii Antigen (BA121GVS) Borrelia afzelii Pko DbpA Antigen (BA121R01) Borrelia afzelii Pko OspC Antigen (BA121R02) Borrelia afzelii Antigen (BA121VS) Borrelia burgdorferi IgG Control Serum (BC121G) Borrelia burgdorferi IgG Control Serum (BC121G) Borrelia burgdorferi IgM Control Serum (BC121M) Borrelia burgdorferi IgG ELISA Kit (ESR121G) Borrelia burgdorferi IgM ELISA Kit (ESR121M)

target relevance
Borrelia garinii
Description Spirochete bacterium that causes Lyme borreliosis, particularly neurological manifestations
Structure Borrelia garinii is a Gram-negative, highly motile spirochete belonging to the Borrelia burgdorferi sensu lato complex and the family Spirochaetaceae. The bacterium possesses a flexible helical morphology and periplasmic flagella that enable corkscrew-like movement through tissues and viscous environments. B. garinii is transmitted primarily through the bite of infected Ixodes ticks and is maintained in nature through transmission cycles involving ticks and avian reservoir hosts. The species is widely distributed throughout Europe and Asia and is one of the principal causative agents of Lyme borreliosis in these regions. Compared with other Borrelia species, B. garinii exhibits a marked neurotropism and is particularly associated with neurological manifestations of Lyme disease. The organism can disseminate from the site of tick inoculation to multiple tissues, including the central and peripheral nervous systems.
Diagnosis The diagnosis of Borrelia garinii infection is performed through a combination of clinical assessment, serological testing, and molecular methods. Laboratory diagnosis typically follows a two-tier testing approach consisting of an initial ELISA or immunoassay followed by confirmatory immunoblot testing when appropriate. Detection of Borrelia-specific IgM and IgG antibodies provides evidence of infection, although antibodies may not be detectable during the earliest stages of disease. Polymerase chain reaction (PCR) assays may be used to detect Borrelia DNA in cerebrospinal fluid, synovial fluid, skin biopsies, or other clinical specimens, particularly in cases involving neurological disease. Cerebrospinal fluid analysis may reveal lymphocytic pleocytosis and intrathecal antibody production in patients with neuroborreliosis. Accurate diagnosis requires correlation of laboratory findings with clinical presentation and exposure history.
Symptoms Borrelia garinii infection commonly presents as Lyme borreliosis following the bite of an infected tick. Early manifestations may include erythema migrans, an expanding skin lesion at the site of the tick bite, accompanied by fever, fatigue, headache, muscle aches, and joint pain. As the infection disseminates, neurological involvement becomes more prominent and may result in Lyme neuroborreliosis characterized by meningitis, cranial nerve palsies, radiculoneuritis, facial paralysis, sensory disturbances, and neuropathic pain. Additional symptoms may include dizziness, cognitive impairment, sleep disturbances, and weakness. If untreated, infection may persist and lead to chronic neurological complications that significantly affect quality of life. Early diagnosis and appropriate antimicrobial therapy generally result in favorable outcomes.

Data

FAQ & Publications

Frequently Asked Questions

What is the primary application of the Borrelia garninii Antigen BA121GVS?

The Borrelia garninii Antigen BA121GVS is primarily used for the detection of IgA, IgG, and IgM antibodies in ELISA assays, specifically indirect and quantitative applications.

How should the Borrelia garninii Antigen BA121GVS be stored to maintain stability?

The antigen should be stored at -65°C or lower, avoiding repeated freeze-thaw cycles. Prior to use, sonication is recommended to ensure proper resuspension. Under these conditions, the antigen is stable for up to 10 years from the date of manufacture.

Is the Borrelia garninii Antigen BA121GVS specific to any Borrelia species?

Yes, the antigen is recombinant and specific to Borrelia garinii, a spirochete bacterium that is associated with Lyme disease.

What is the concentration and form of the Borrelia garninii Antigen BA121GVS provided?

The product is supplied as a liquid recombinant antigen with a lot-specific concentration provided in mg/mL, and the available size is 1 mg.

Publications

pmid	title	authors	citation
We haven't added any publications to our database yet.

Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from the PubMed database provided by the United States National Library of Medicine at the National Institutes of Health.